Bart Denys, MD
Interventional Cardiology · Thibodaux, LANPI 1659378685
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,900 of the $29,398 with a category attached, or 60.9%. 28 manufacturers reported payments, led by Pfizer at 44.2% of the total. Reporting peaked in 2019 at $16,877 and has fallen 97.2% since, to $477 in 2025.
Across 320 payments — averaging $91.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$13K
- AstraZeneca$9K
- E.r. Squibb & Sons, L.L.C.$4K
- Johnson & Johnson$717
- Novartis$560
- Merck$419
- plus $2K from 22 others
What the payments were for
- Consulting fees$4,20014%
- Speaking & faculty fees$17,90061%
- Travel & lodging$2,5059%
- Food & beverage$4,79316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 94 | $12,986 |
| AstraZeneca | 18 | $8,804 |
| E.r. Squibb & Sons, L.L.C. | 10 | $4,352 |
| Johnson & Johnson | 45 | $717 |
| Novartis | 40 | $560 |
| Merck | 25 | $419 |
| Alnylam Pharmaceuticals Inc. | 9 | $227 |
| Amgen | 14 | $209 |
| Boehringer Ingelheim | 11 | $174 |
| Kowa Pharmaceuticals America, Inc. | 9 | $118 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $105 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Abiomed | 2 | $81 |
| Regeneron Healthcare Solutions, Inc. | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $67 |
| Novo Nordisk | 3 | $57 |
| Lexicon Pharmaceuticals, Inc. | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $37 |
| Itamar Medical Inc | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Ancora Heart, Inc. | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 2 | $29 |
| Bayer | 2 | $27 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,398 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 695 | $598,599 |
| EntrestoSacubitril/Valsartan | 218 | $229,658 |
| Repatha SureclickEvolocumab | 172 | $113,040 |
| XareltoRivaroxaban | 76 | $61,815 |
| BrilintaTicagrelor | 46 | $39,387 |
| Rosuvastatin Calcium | 2,633 | $30,573 |
| NexletolBempedoic Acid | 29 | $21,714 |
| Praluent PenAlirocumab | 35 | $20,268 |
| Nebivolol Hcl | 269 | $17,323 |
| JardianceEmpagliflozin | 21 | $16,332 |
| Ezetimibe | 832 | $16,178 |
| LivaloPitavastatin Calcium | 24 | $15,778 |
| Ranolazine ErRanolazine | 153 | $15,297 |
| Metoprolol Succinate | 1,033 | $13,937 |
| Nifedipine ErNifedipine | 636 | $13,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12,986 | $598,599695 claims |
| NovartisEntresto | $560 | $229,658218 claims |
| Johnson & JohnsonXarelto | $717 | $61,81576 claims |
| AstraZenecaBrilinta, Farxiga | $8,804 | $52,53465 claims |
| Esperion Therapeutics, Inc.Nexletol | $37 | $21,71429 claims |
| Boehringer IngelheimJardiance | $174 | $16,33221 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $118 | $15,77824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Thibodaux
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
- Jorge CastellanosBaton Rouge$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.